Adjuvant oxaliplatin with S-1 (SOX) versus S-1 for stage II-III gastric cancer (CAPITAL): A randomized, open-label, phase 3 trial.
MedAug 14, 2026 (epub)
Clinical ResearchOncology (Medical)
Run-Cong Nie, Shi Chen, Jin Wan et al.
✦ AI-curated · Sources linked
In 30 seconds
The CAPITAL trial, a multicenter, randomized phase 3 study, evaluated the efficacy of adjuvant oxaliplatin plus S-1 (SOX) versus S-1 alone in patients with stage II-III gastric or gastroesophageal junction adenocarcinoma post-gastrectomy. The study found that the 5-year overall survival rate was 70.9% for the SOX group compared to 62.9% for the S-1 group (HR, 0.74; p = 0.018).
Key findings
- 5-year overall survival rates were 70.9% for SOX vs 62.9% for S-1 (HR, 0.74; p = 0.018).
- 3-year disease-free survival rates were 71.2% for SOX vs 65.1% for S-1 (HR, 0.76).
- Grade 3-4 treatment-related adverse events occurred in 25% of SOX patients vs 13% of S-1 patients.
Why it matters
This study highlights the potential benefits of combining oxaliplatin with S-1 in improving survival outcomes for patients with resectable gastric cancer, which may influence treatment protocols in oncology.